Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cytomegalovirus peptide vaccine (PepVax) - Helocyte

Next Previous
X
Search
Drug Profile

Cytomegalovirus peptide vaccine (PepVax) - Helocyte

Alternative Names: CMV fusion peptide vaccines - Helocyte; CMVPepVax; CMVpp65-A*0201 peptide vaccine - Helocyte; Tet-CMV

Latest Information Update: 27 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator City of Hope National Medical Center
  • Developer City of Hope National Medical Center; Helocyte; National Cancer Institute (USA); University of Minnesota
  • Class Cytomegalovirus vaccines; Immunotherapies; Peptide vaccines; Recombinant fusion proteins; T lymphocyte cell therapies; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cytomegalovirus infections

Most Recent Events

  • 11 Dec 2021 Efficacy data from a phase II trial in Cytomegalovirus infections was presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-2021)
  • 23 Aug 2017 Phase-II development is ongoing in USA (NCT02396134)
  • 04 May 2015 City of Hope and National Cancer Institute plans a phase II trial in Cytomegalovirus infections (Prevention, in HLA A*0201 cytomegalovirus-seropositive with haematological malignancies undergoing donor stem cell transplant) in USA (SC) (NCT02396134; 9178335)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top